Defining Corneal Schwann cells in Injury

定义损伤中的角膜雪旺细胞

基本信息

  • 批准号:
    10308502
  • 负责人:
  • 金额:
    $ 23.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-12-01 至 2023-11-30
  • 项目状态:
    已结题

项目摘要

The transparent cornea is a highly innervated tissue and sustains significant nerve damage during common procedures such as corneal transplantation and vision correction. Unfortunately, the restoration of corneal sensory function after damage is usually inadequate due to aberrant and poor regeneration of axons. In vascularized tissues, such as the sciatic nerve and spinal cord Schwann cells (SCs) are known to support axonal regeneration after injury. However, little is known how corneal SCs respond to injury or surgical procedures as this cell types has not previously been investigated. Studies performed in sciatic injury models reveal that both the genetic encoded factors of SCs, as well as the extracellular matrix components govern the axonal repair process. The dedifferentiation of SCs into a repair SCs – a transient cell type – that re-differentiates into a terminal SC is a hallmark of SC-driven mechanisms in axonal regeneration. In the cornea, the bulk of sensory axons are unmyelinated axons, except at the limbus where they are myelinated. It is presumed that lesions of nonmyelinating corneal axons also enlist the support of their respective SCs for axonal regeneration, mirroring similar activities of SCs of injured vascularized tissues. This idea has not been formally tested before, as experimental evidence to support or refute this paradigm is lacking. To learn what genes are expressed specifically in corneal SCs, we performed a single cell RNA sequence analysis of the rabbit cornea and identified the corneal SC transcriptome. With cross-species validation of several SC-specific target proteins in mouse corneas and validation of a transgenic mouse line expressing proteolipid protein 1-enhanced green fluorescent protein (Plp1-eGFP), we demonstrated SC-specific reporter gene expression in vivo. In this exploratory R21 grant, we propose two aims. In specific aim 1, we will exploit the Plp1- eGFP reporter transgenic line in a corneal stromal injury model causing nerve severance and investigate corneal SC to myofibroblast differentiation over the course of axonal degeneration and repair. These studies will help define whether corneal SCs differentiate into myofibroblasts and nature of injury that promotes this aberrant phenotype. In specific aim 2, we will investigate the wingless (Wnt) signaling pathway in corneal SCs, as molecular components of this pathway showed differential high expression in SCs compared to other corneal cells. We plan to investigate how modulation of the Wnt inhibitor Dickkopf-1 (Dkk1) governs corneal axonal regeneration after injury and effects on corneal mechanical sensation. Together, these objectives will help to lay down the foundation to identify novel targets for SC-therapeutics towards improvement of corneal axonal growth and sensory impairment.
透明角膜是高度受神经支配的组织,并且在手术期间维持显著的神经损伤。 常见的手术,如角膜移植和视力矫正。可惜 损伤后角膜感觉功能的恢复通常是不充分的, 轴突再生。在血管组织中,如坐骨神经和脊髓许旺氏 已知神经干细胞(SC)在损伤后支持轴突再生。然而,很少有人知道如何 角膜干细胞对损伤或外科手术有反应,因为这种细胞类型以前没有被 研究了在坐骨神经损伤模型中进行的研究表明, SC的因子以及细胞外基质组分控制轴突修复过程。 干细胞去分化为修复干细胞--一种瞬时细胞类型--再分化为 终末SC是轴突再生中SC驱动机制的标志。在角膜中,大部分 感觉轴突的大多数是无髓鞘轴突,除了在利姆布斯处它们是有髓鞘的。是 假设非髓鞘化角膜轴突的病变也获得了它们各自的支持, SC用于轴突再生,反映了损伤的血管化组织的SC的类似活性。 这一想法之前没有经过正式的测试,作为实验证据来支持或反驳这一点 缺乏范式。为了了解哪些基因在角膜干细胞中特异性表达,我们进行了 对兔角膜进行单细胞RNA序列分析,鉴定出角膜SC 转录组在小鼠中对几种SC特异性靶蛋白进行跨物种验证 角膜和表达蛋白脂质蛋白1-增强的绿色的转基因小鼠系的验证 荧光蛋白(Plp 1-eGFP),我们证明了SC特异性报告基因在体内的表达。 在这个探索性的R21赠款中,我们提出了两个目标。在具体目标1中,我们将利用Plp 1- eGFP报告基因转基因系在角膜基质损伤模型中引起神经切断, 研究角膜SC在轴突变性过程中向肌成纤维细胞的分化, 修复.这些研究将有助于确定角膜SC是否分化为肌成纤维细胞, 促进这种异常表型的损伤性质。在具体目标2中,我们将研究 角膜SC中的无翅(Wnt)信号通路,作为该通路的分子组分 与其他角膜细胞相比,在SC中显示差异性高表达。我们计划调查 Wnt抑制剂Dickkopf-1(Dkk 1)的调节如何控制角膜轴突再生, 损伤和对角膜机械感觉的影响。这些目标将有助于奠定 为确定SC治疗的新靶点奠定基础, 轴突生长和感觉障碍。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROYCE MOHAN其他文献

ROYCE MOHAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROYCE MOHAN', 18)}}的其他基金

Unraveling the corneal and retinal mechanisms of chemical injury
揭示化学损伤的角膜和视网膜机制
  • 批准号:
    10882069
  • 财政年份:
    2023
  • 资助金额:
    $ 23.86万
  • 项目类别:
Targeting Citrullination in Ocular Chemical Injury
针对眼部化学损伤的瓜氨酸化
  • 批准号:
    10206486
  • 财政年份:
    2021
  • 资助金额:
    $ 23.86万
  • 项目类别:
Targeting Citrullination in Ocular Chemical Injury
针对眼部化学损伤的瓜氨酸化
  • 批准号:
    10459390
  • 财政年份:
    2021
  • 资助金额:
    $ 23.86万
  • 项目类别:
Targeting Citrullination in Ocular Chemical Injury
针对眼部化学损伤的瓜氨酸化
  • 批准号:
    10516386
  • 财政年份:
    2021
  • 资助金额:
    $ 23.86万
  • 项目类别:
Targeting Citrullination in Ocular Chemical Injury
针对眼部化学损伤的瓜氨酸化
  • 批准号:
    10705952
  • 财政年份:
    2021
  • 资助金额:
    $ 23.86万
  • 项目类别:
PAD4 in Retinal Gliosis
PAD4 与视网膜神经胶质增生
  • 批准号:
    9436900
  • 财政年份:
    2018
  • 资助金额:
    $ 23.86万
  • 项目类别:
Novel Modular Vascular Patterning Assay for HTS
HTS 的新型模块化血管模式分析
  • 批准号:
    7648164
  • 财政年份:
    2008
  • 资助金额:
    $ 23.86万
  • 项目类别:
Novel Modular Vascular Patterning Assay for HTS
HTS 的新型模块化血管模式分析
  • 批准号:
    7527007
  • 财政年份:
    2008
  • 资助金额:
    $ 23.86万
  • 项目类别:
Novel Modular Vascular Patterning Assay for HTS
HTS 的新型模块化血管模式分析
  • 批准号:
    8243126
  • 财政年份:
    2008
  • 资助金额:
    $ 23.86万
  • 项目类别:
Molecular targets of Corneal Anti-fibrosis
角膜抗纤维化的分子靶点
  • 批准号:
    8589414
  • 财政年份:
    2007
  • 资助金额:
    $ 23.86万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 23.86万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 23.86万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 23.86万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.86万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 23.86万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 23.86万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 23.86万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 23.86万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 23.86万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 23.86万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了